Assessment of HER-2/neun status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard

American Journal of Clinical Pathology

Volumn 116, Issue 4, 2001, Pages 495-503

  Wang, Sijian ^a   Saboorian, M Hossein ^a   Frenkel, Eugene P ^a   Haley, Barbara B ^a   Siddiqui, Momin T ^a   Gokaslan, Sefik ^a   Wians Jr , Frank H ^a   Hynan, Linda ^a   Ashfaq, Raheela ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

ACIS; Breast cancer; ErbB 2; Fluorescence in situ hybridization; HER 2 neu; Image analysis; Immunohistochemistry

Indexed keywords

ANALYTIC METHOD; ARTICLE; AUTOMATION; BREAST CANCER; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING SYSTEM; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; ROC CURVE; STANDARD; TISSUE FIXATION; BREAST TUMOR; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION; GENETICS; IMAGE PROCESSING; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST NEOPLASMS; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0035542711     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/TMUW-G4WB-LXJ2-FUDN     Document Type: Article

References (32)

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
2. Studies of the Her/neu proto-oncogene in human breast and ovarian cancer
3. ERBB2 oncogene in human breast cancer and its clinical significance
4. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32
5. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
6. HER-2/neu signal transduction in human breast and ovarian cancer
7. Strategies for the analysis of oncogene overexpression: Studies of the neu oncogene in breast carcinoma
8. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
9. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer
10. Prognostic importance of c-erbB-2 expression in breast cancer
11. The prognostic value of c-erbB2 in primary breast carcinomas: A study on 942 cases
12. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
13. Prognostic and predictive factors in breast cancer by immunohistochemical analysis
14. C-erbB-2 expression and response to adjuvant therapy in women with node-positive breast cancer
15. Humanization of an anti-p185HER2 antibody for human cancer therapy
16. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts
17. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER-2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase III trial
18. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
19. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
20. HER-2/neu testing in breast carcinoma: A combined immunohistochemical fluorescence in situ hybridization approach
21. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer
22. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma
23. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma
24. Testing for erbB-2 by immunohistochemistry in breast cancer
25. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
26. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
27. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials
28. Effective HER-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH
29. Quantitative immunohistochemical assay for hormonal receptors: Technical aspects and biological significance
30. Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus: A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR